Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR 905.05
+39.55 (4.57%)
Aug 25, 2025, 3:30 PM IST
Strides Pharma Science Revenue
Strides Pharma Science had revenue of 11.20B INR in the quarter ending June 30, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to 46.31B, up 10.03% year-over-year. In the fiscal year ending March 31, 2025, Strides Pharma Science had annual revenue of 45.65B with 17.36% growth.
Revenue (ttm)
46.31B
Revenue Growth
+10.03%
P/S Ratio
1.80
Revenue / Employee
14.03M
Employees
3,301
Market Cap
83.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 45.65B | 6.75B | 17.36% |
| Mar 31, 2024 | 38.90B | 2.02B | 5.47% |
| Mar 31, 2023 | 36.88B | 6.18B | 20.13% |
| Mar 31, 2022 | 30.70B | -2.46B | -7.41% |
| Mar 31, 2021 | 33.16B | 5.64B | 20.49% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 236.08B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
Strides Pharma Science News
- 27 days ago - Strides Pharma shares hit 52-week high, jumps 3% after Q1 PAT jumps 81% YoY - Business Upturn
- 27 days ago - Strides Pharma Q1 Results: Revenue rises 6.2% YoY to Rs 1119 crore, Net Profit at Rs 105.6 crore - Business Upturn
- 4 months ago - Strides Pharma receives USFDA approval for Celecoxib Capsules - Business Upturn
- 4 months ago - Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation - Business Upturn
- 7 months ago - Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25 - Business Upturn
- 7 months ago - Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY - Business Upturn
- 7 months ago - Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio - Business Upturn
- 10 months ago - Strides Pharma Science Q2 FY25 Results: Net profit surges to ₹93.7 crore, US revenues hit historic high - Business Upturn